MarketCapExport financials
Gritstone Oncology (GRTS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Gritstone Oncology Income Statement 2023-2011 | GRTS
Brief overview of financial performance at Gritstone Oncology
This overview is based on financial performance over the past five years. Revenue reported by Gritstone Oncology was $1.2 million at the beginning of the period and $16.3 million at the end. Across the full period, sales moved by +1276.9%; the average annual rate was 69%. The annual growth rate indicates an exceptionally strong top-line trend.
Over the period, EBITDA shifted from −61.6 million dollars to −132 million dollars, a change of −114.3%. EBITDA lagged revenue, showing weaker operating momentum. At the operating-margin level, the figure shifted from −5191.5% to −807.8%. Higher profitability strengthens the quality of operating growth.
The net financial result changed from −$64.8 million to −$138 million. The negative result deepened, showing weaker final efficiency.
Market capitalization changed from 115 million dollars to 276 million dollars (+140.7%). The financial trend was stronger than the market valuation.
Overall conclusion
The five-year picture requires weighing both strengths and weaknesses. The financial profile benefits from an improving EBITDA margin and sales growth. The main areas of concern are limited operating profitability and lower net income. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Gritstone Oncology
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
276 M | 210 M | 402 M | 513 M | 282 M | 115 M | - | - | - | - | - | - | - |
Shares |
116 M | 90.9 M | 78.9 M | 37.8 M | 33.6 M | 8.92 M | 2 M | 1.67 M | - | - | - | - | - |
Historical Prices |
2.39 | 2.31 | 5.1 | 13.6 | 8.4 | 12.9 | - | - | - | - | - | - | - |
Net Income |
-138 M | -120 M | -75.1 M | -105 M | -94.4 M | -64.8 M | -41.4 M | -18.8 M | - | - | - | - | - |
Revenue |
16.3 M | 19.9 M | 48.2 M | 4.04 M | 4.36 M | 1.19 M | - | - | - | - | - | - | - |
Operating Income |
-140 M | -120 M | -75.2 M | -106 M | -97.9 M | -65.6 M | -41.8 M | -19 M | - | - | - | - | - |
Interest Expense |
4.04 M | 1.24 M | 37 K | 12 K | - | - | - | - | - | - | - | - | - |
EBITDA |
-132 M | -114 M | -68.9 M | -99.4 M | -93.2 M | -61.6 M | -39.8 M | -18.2 M | - | - | - | - | - |
Operating Expenses |
156 M | 140 M | 123 M | 110 M | 102 M | 66.8 M | 41.8 M | 19 M | - | - | - | - | - |
General and Administrative Expenses |
28.8 M | 29 M | 25.9 M | 21.4 M | 19.4 M | 11.8 M | 6.07 M | 5.06 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Gritstone Oncology
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
143 M | 118 M | 97.6 M | 115 M | 115 M | 114 M | 86.9 M | 86.6 M | 86.4 M | 86.3 M | 69 M | 77.8 M | 76.7 M | 76 M | 47.6 M | 37.8 M | 37.3 M | 36.8 M | 36.3 M | 35.7 M | 33.6 M | 28.9 M | 28.8 M | 2.45 M | 2.35 M | 2.22 M | 2.15 M | 2.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-23.4 M | -40.4 M | - | -38.4 M | -35.3 M | -34 M | - | -30 M | -29.5 M | -28.9 M | - | -28.1 M | -25.1 M | 7.92 M | -27.2 M | -26.1 M | -25.9 M | -26.2 M | -27.7 M | -27.5 M | -21.2 M | -18 M | -17.3 M | -18.6 M | -15.5 M | -13.4 M | -17.4 M | -9.45 M | -7.79 M | -6.77 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
921 K | 1.74 M | - | 1.56 M | 1.96 M | 2.44 M | - | 3.02 M | 5.47 M | 7.19 M | - | 2.61 M | 2.84 M | 39.7 M | 1.35 M | 939 K | 488 K | 1.26 M | 884 K | 984 K | 1.15 M | 1.35 M | 1.09 M | 96 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-27.6 M | -39.8 M | - | -38.6 M | -35.7 M | -34.8 M | - | -29.9 M | -29.7 M | -29 M | - | -28.2 M | -25.2 M | 7.9 M | -27.1 M | -26.1 M | -26.1 M | -26.7 M | -28.3 M | -28.5 M | -22.2 M | -18.9 M | -18 M | -18.6 M | -15.5 M | -13.4 M | -17.6 M | -9.49 M | -7.85 M | -6.84 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
1.3 M | 1.3 M | - | 991 K | 985 K | 844 K | - | 551 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-26 M | -38.1 M | - | -36.6 M | -33.8 M | -33 M | - | -28.2 M | -28.2 M | -27.4 M | - | -26.6 M | -23.6 M | 9.49 M | -27.1 M | -24.4 M | -24.4 M | -25 M | -28.3 M | -27.3 M | -21.1 M | -17.9 M | -18 M | -17.6 M | -14.5 M | -12.5 M | -17.6 M | -8.99 M | -7.85 M | -6.84 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
28.5 M | 41.5 M | - | 40.2 M | 37.7 M | 37.3 M | - | 32.9 M | 35.1 M | 36.2 M | - | 30.8 M | 28 M | 31.8 M | - | 27.1 M | 26.5 M | 27.9 M | - | 29.5 M | 23.4 M | 20.3 M | - | 18.7 M | 15.5 M | 13.4 M | - | 9.49 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
7.7 M | 8.5 M | - | 7.41 M | 6.72 M | 6.74 M | - | 6.46 M | 7.79 M | 7.96 M | - | 6.37 M | 5.94 M | 6.94 M | - | 5.03 M | 5.26 M | 5.46 M | - | 4.58 M | 4.84 M | 4.38 M | - | 3.09 M | 2.81 M | 2.04 M | - | 1.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Gritstone Oncology (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
Russia